Clinical trials: Disease Exacerbation
COPD
Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study
The aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with COPD.
- Trial name
- NCT01645800
- Testing
- Lysozyme hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 408 people
- Sponsor
- Eisai Co., Ltd.
Bronchial Asthma
Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.
Many studies have investigated the efficacy and safety of Intravenous magnesium sulfate and inhaled steroids in addition to the standard treatment for patients with severe asthma attacks.
- Trial name
- NCT02455687
- Testing
- Hi-dose iv MgSO4, Nebulized budesonide, Std-dose iv MgSO4
- Where
- Qatar
- Volunteers
- 240 people
- Sponsor
- Hamad Medical Corporation
Bronchitis, Bronchitis, Chronic
A Study of the Safety and Effectiveness of Levofloxacin Compared With Cefaclor in the Treatment of Adults With Chronic Bronchitis Experiencing Rapid Onset of Worsening of Symptoms Caused by Bacteria
The purpose of this study is to evaluate the safety and effectiveness of levofloxacin, an antibiotic, compared with cefaclor, another antibiotic, in the treatment of adults with chronic bronchitis experiencing rapid onset of…
- Trial name
- NCT00257140
- Testing
- levofloxacin
- Volunteers
- 367 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cystic Fibrosis
Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study
The purpose of this study is to determine the efficacy and safety of chronic treatment with inhaled dry powder mannitol in subjects with cystic fibrosis.
- Trial name
- NCT00446680
- Testing
- Mannitol
- Where
- 29 sites in Australia, Ireland and 1 more
- Volunteers
- 340 people
- Sponsor
- Syntara
Schizophrenia
Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
This is the long-term open label extension (OLE) of the study PRISMA-3 (NCT03160521). Those patients who complete participation in the main segment of the study (double blind) together with other clinically stable not previously…
- Trial name
- PRISMA-3_OLE (NCT03870880)
- Testing
- Risperidone ISM 75 mg, Risperidone ISM 100 mg
- Where
- 24 sites in United States, Ukraine
- Volunteers
- 215 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
F17464 in Acute Schizophrenia Trial
The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia.
- Trial name
- FAST (NCT02151656)
- Testing
- F17464
- Where
- 27 sites in France, Hungary and 3 more
- Volunteers
- 158 people
- Sponsor
- Pierre Fabre Medicament
Acute Otitis Media (AOM), Strep Pharyngitis
Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and Asthma
This study evaluates the diagnostic performance, usability, and clinical utility of the Medentum Diagnostik platform, a multisensor device with integrated software and artificial intelligence, in pediatric patients with asthma…
- Conditions
- Acute Otitis Media (AOM), Strep Pharyngitis, Asthma Exacerbation, Pediatric Asthma
- Trial name
- NCT07500532
- Testing
- Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of AOM and strep pharyngitis, Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of wheeze/asthma exacerbation, Routine Asthma Management (in-person and telehealth visits)- Control Group
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Medentum Innovations
Asthma
A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients
The present study is designed to collect data on real world experience on use of Medrol in acute asthma in Indian patients.
- Trial name
- NCT00971893
- Testing
- Oral Methylprednisolone Tablets
- Sponsor
- Pfizer
Copd, COPD Exacerbation
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.
Preferred pharmacological management for COPD according to the GOLD guidelines are the long-acting anticholinergic LAMAs (Long-Acting / Short-Acting Muscarinic Antagonists), and long-acting β 2-Agonists LABA (Long-acting LABA) /…
- Trial name
- ARGO (NCT05426915)
- Where
- Greece
- Volunteers
- 750 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Crohn Disease, Ulcerative Colitis
Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease
The goal of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoperfusion using the Efferon® LPS device in patients with ulcerative colitis and Crohn disease.
- Conditions
- Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
- Trial name
- NCT07383597
- Testing
- Efferon LPS
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- Efferon JSC
Schizophrenia
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.
- Trial name
- NCT00044044
- Testing
- Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg
- Where
- 34 sites in United States
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum…
- Trial name
- NCT02522299
- Testing
- GSK2269557, DISKUS, ELLIPTA
- Where
- 6 sites in Canada, Denmark
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Chronic Bronchitis
A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)
This trial is a research drug study to compare the effects of two antibiotics for the treatment of acute exacerbation of chronic bronchitis
- Trial name
- NCT00254566
- Testing
- Moxifloxacin, Azithromycin SR
- Where
- 34 sites in China, Malaysia and 4 more
- Volunteers
- 398 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
CareCOPD - COPD Home Monitoring Study
This is a pilot study to demonstrate early validation of objective home-monitoring of Chronic obstructive pulmonary disease (COPD) patients by combining accurate and relevant patient data of medication and lung function (lung…
- Trial name
- NCT04918095
- Testing
- CareCOPD Platform
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cognita Labs LLC
Schizophrenia
Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia.
- Trial name
- NCT00768612
- Testing
- SCA-136 50mg/day, SCA-136 150 mg/day, SCA-136 300mg/day
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
COPD, Chronic Obstructive Pulmonary Disease
The PALP™-COPD Trial (Low-Flow CO2-Removal (ECCO2-R) in Exacerbated COPD)
A Multicenter, Randomized, Controlled Trial to Determine Safety and Efficacy of Pump Assisted Lung Protection (PALP™) for Low Flow Carbon Dioxide (CO2) Removal in Conjunction with Liberation from Mechanical Ventilation Compared…
- Trial name
- PALP-COPD (NCT02107222)
- Testing
- CO2-Removal (PALP-Device/MaquetCP)
- Where
- Germany
- Sponsor
- Maquet Cardiopulmonary GmbH
COPD
This is a Multicenter, Prospective and Retrospective and Descriptive Epidemiology Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Korea
This study is designed as a multicenter, prospective and retrospective and descriptive epidemiology study. This study is planned to evaluate 2 years of exacerbation in COPD patients and to investigate correlation of COPD disease…
- Trial name
- EPOCH (NCT01419379)
- Where
- 14 sites in South Korea
- Volunteers
- 1,118 people
- Sponsor
- Takeda
Lung Diseases, Bronchitis, Chronic
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis
Moxifloxacin, is being tested at approximately 60 study centres in 15 countries to determine if this drug, when taken periodically in addition to the patients normal treatment, is effective at reducing the number of flare-ups of…
- Trial name
- NCT00473460
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- 78 sites in United States, Andorra and 13 more
- Volunteers
- 1,404 people
- Sponsor
- Bayer
Schizophrenia
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self.
- Trial name
- 509 JPN Schz (NCT05368558)
- Testing
- Cariprazine
- Where
- 52 sites in Japan, Taiwan
- Volunteers
- 34 people
- Sponsor
- AbbVie
Schizophrenia
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with…
- Trial name
- NCT07038876
- Testing
- ML-007C-MA BID, ML-007C-MA QD
- Where
- 24 sites in United States
- Volunteers
- 307 people
- Sponsor
- MapLight Therapeutics